Turning Point Therapeutics Initiates Phase 1 Clinical Study of Tpx-0022, a Novel Met Inhibitor Targeting Advanced Solid Tumors

by NASDAQ Market News July 31, 2019

NASDAQ Market News
Click here to email author

Generex Biotechnology Introduces Pantheon Medical, the Newest Member of the NuGenerex Family of Companies

SELLAS Advances Galinpepimut-S (GPS) in Combination with KEYTRUDA® (pembrolizumab) Program with Dosing of First Patient in Phase 1/2 Basket Study

Ads